deaths from glp 1 Nurse's death linked to weight-loss drug Mounjaro approved on NHS GLP-1 receptor agonists show promise

Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, and Vanita R

Combining naltrexone and semaglutide may enhance weight loss through different biological pathways, but safety and efficacy depend on individual health factors and medical supervision

Novo Nordisk and Eli Lilly, the dominant players in the GLP-1R market, are expected to collectively capture 94 per cent of the projected $142 billion GLP-1R sales by 2030

ANNOUNCEMENT Introducing Noom GLP-1 - compounded semaglutide starting at just $149, making the weight loss journey more affordable, accessible, and sustainable

Simply place your loaded syringe in the Inject-Ease, place the tip against your skin, and press the button to automatically deliver the needle through the skin

Lower GLP-1 doses for athletes: less appetite suppression, fewer side effects, maintained fueling ability, still losing fat